Love Maharashtra? Then you wil love Marathikatta!
Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
INDIAN CHEMISTS BOYCOTT GLAXO, NOVARTIS

 

 

 

Maharashtra phases out nerve tissue-based rabies vaccine

12 June, 2005

Maharashtra state to use only tissue culture vaccines (TCVs) for preventive rabies care.

BY OUR PHARMA CORRESPONDENT

The state-run hospitals of Maharashtra, India have switched over to tissue culture vaccine (TCV) to control rabies from the beginning of June 2005.

The last vial of the erstwhile neural tissue based anti-rabies vaccine went off-shelf from 31st of May, 2005. 

The Indian public sector firm, Haffkine’s Bio Pharmaceuticals was the chief supplier of anti-rabies vaccine to Maharashtra state hospitals. The company was supplying around 4 million units of neural tissue vaccine (NTV), annually.

Out of the total yearly requirement of nearly 14 million units, 7-9 million units sourced from the public sector. The rest was purchased from the public and private sector manufacturers from other states of India.

The Mumbai-based Haffkine’s Bio had stopped producing the vaccines from December 1, 2004 following the recommendation by WHO to phase out neural tissue vaccines (NTVs) and use only tissue culture vaccines (TCVs) to preventive rabies care. However, the units which have already been manufactured were allowed to stay in the market with a 5-months’ deadline.

According to sources, public hospitals across the state have already started feeling the pinch and have been reeling under acute shortage of ARVs for the last couple of months.

ARV is one of the essential stocks in all public health centres as the city of Mumbai alone reports about 25,000 dog-bites per month.

However, government sourced maintained that to avert the acute crisis of ARVs, the health authorities have already started negotiations to procure vaccines from leading tissue culture vaccine (TCV) producers like Aventis.

BY OUR PHARMA CORRESPONDENT

Featured Business stories:

Contraceptive from Neem, courtesy DRDO  

100 per cent FDI in non-news media permitted  

IA lures peak season travellers  

Ranbaxy HIV/AIDS drug gets US FDA approval

India world's 3rd largest economy by 2030

Bluetooth shipments cross 5 million per week  

Seychelles has 2 of world's 3 most expensive hotels  

SEBI bars UBS for one year  

Last long, really long - new sex drug soon  

Thomas Cook plans to launch Forex ATMs 

Rahul Bajaj takes Force Motors to court

God's own airline  

CyberMedia announces IPO

Emirates Airline starts daily flights between Dubai, Seoul  
 
 Air India to buy 50 Boeings  

Credit policy 2005-2006  

Qatar Airways announces three new routes  

Diabetes drug Byetta approved by USFDA

Kingfisher Airlines takes flight

Kingfisher takes delivery of first Airbus 320  

Shoppers Stop IPO delayed, then permitted 

India Infoline IPO oversubscribed 7.34 times

HLL March Quarter results  

Hindustan Times files for IPO

NDTV Profit: Quick look

Ratan Tata: People's tycoon
DWS Man of the Year 2004

TCS picked by Ferrari for IT services

N R Narayana Murthy and the art of bluster

Jet Airways to go for Rs 1500 cr IPO

Royal Air, Kingfisher, Go race to the sky

Kerala's own budget airline?

Anil, Mukesh and Reliance - to split or not?

Birla Blues! The story so far

India Infoline announces IPO

Credit policy 2005-2006  

PERSONAL FINANCE

ABN Amro credit cards

Standard Chartered credit cards
 

Citibank India credit cards

ICICI Bank credit cards

HSBC Bank credit cards

ICICI Bank home loans

UTI Bank home loans

Archived Business Stories

 

Latest updates    Contact Us - Feedback    About Us